Prevalence and characteristics of migraine in CADASIL by Guey, Stephanie et al.
Original Article
Prevalence and characteristics
of migraine in CADASIL
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Abstract
Background and objective: Migraine with aura (MA) is a major symptom of cerebral autosomal dominant arterio-
pathy with subcortical infarcts and leukoencephalopathy (CADASIL). We assessed the spectrum of migraine symptoms
and their potential correlates in a large prospective cohort of CADASIL individuals.
Methods: A standardized questionnaire was used in 378 CADASIL patients for assessing headache symptoms, trigger
factors, age at first attack, frequency of attacks and associated symptoms. MRI lesions and brain atrophy were quantified.
Results: A total of 54.5% of individuals had a history of migraine, mostly MA in 84% of them; 62.4% of individuals with
MA were women and age at onset of MA was lower in women than in men. Atypical aura symptoms were experienced
by 59.3% of individuals with MA, and for 19.7% of patients with MA the aura was never accompanied by headache. MA
was the inaugural manifestation in 41% of symptomatic patients and an isolated symptom in 12.1% of individuals. Slightly
higher MMSE and MDRS scores and lower Rankin score were detected in the MA group.
Conclusion: MA is observed in almost half of all CADASIL patients. Atypical aura symptoms are reported by more than
one in two of them. MA is often inaugural, can remain isolated and is not associated with the severity of the disorder.
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Introduction
Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy
(CADASIL) is the most frequent hereditary ischemic
small vessel disease of the brain (1). Mutations in the
extracellular domains of the NOTCH3 receptor respon-
sible for the disease may favor oligomerization of the
protein and its accumulation in the wall of arterioles
and capillaries (2). CADASIL is responsible for
recurrent ischemic stroke during mid-adulthood
and can lead to severe motor disability and cognitive
decline (3–5).
Migraine with aura (MA) is a major symptom of
CADASIL. A positive history of MA has been previ-
ously reported in 20% to 40% of symptomatic individ-
uals. MA can occur several decades before stroke
events. In contrast to MA, migraine without aura
(MO) was not found to be more prevalent in
CADASIL than in different large population-based
samples (3,4,6–8). Mean age at onset of MA was pre-
viously found to be close to 30 years in CADASIL (9).
In a retrospective study of 41 CADASIL patients with
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MA, Vahedi et al. reported that a large proportion of
CADASIL patients experienced aura without headache
or atypical aura such as hemiplegic or basilar aura, pro-
longed aura or acute-onset aura (9). Further analysis
of the spectrum of MA symptoms and of their correlates
is, however, hampered by the limited number of patients
and retrospective nature of previous studies.
Herein, we aimed to analyze the frequency and clin-
ical features of migraine symptoms with their clinical
and imaging correlates in a large prospective cohort of
378 CADASIL individuals.
Methods
Participants and clinical assessment
Patients were recruited between 2003 and 2011 in a
large prospective cohort study of CADASIL patients
performed in Lariboisière Hospital, Paris, and in the
Ludwig Maximilians University Neurology Clinic,
Munich. All patients recruited in both centers during
the inclusion period were included in this study. All
patients carried a typical mutation of the NOTCH3
gene responsible for the disease or were diagnosed by
the presence of pathognomonic granular osmiophilic
deposits in skin biopsy (1,2). They were aged 18 years
or older at inclusion and gave their written consent to
participate in the study. An independent ethics commit-
tee approved the study in both centers.
In each center, an experienced neurologist collected
during an individual consultation a detailed history of
headache symptoms as well as multiple clinical and
demographic data such as age, sex, comorbidities, car-
diovascular risk factors (arterial hypertension, diabetes,
smoking and alcohol habits, dyslipidemia), history of
stoke or transient ischemic attack (TIA), psychiatric
symptoms, epilepsy, gait disturbances and cognitive
impairment. Dementia was diagnosed according to
the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) criteria.
Headache symptoms were classified according to the
International Classification of Headache Disorders
(10). A neurologist collected all information relative
to headache history based on a standardized question-
naire. The following items were systematically col-
lected: the type of migraine attacks (MO, MA), the
most frequent triggering factors, the age at first
attack, the mean frequency of attacks, the mean dur-
ation of headache during the two years prior to inclu-
sion, the characteristics of headache (hemicrania,
pulsatility) and the frequency of associated symptoms
(nausea, vomiting, phonophobia, photophobia). For
these different items, we pooled percentages of patients
in categories as ‘‘often’’ (more than half of attacks) and
‘‘sometimes’’ (less than half of attacks). In patients
reporting MA, the following items were also collected:
the type of aura symptoms (visual, sensitive, motor,
aphasic or other symptoms), the mean duration of
aura, the occurrence of a typical ‘‘marche migraineuse’’
(progressive development of aura symptoms over 5
minutes) and the chronological relationship of aura
with headache. Aura without headache was considered
as part of MA. Aura symptoms were considered to
correspond to a typical aura when they were visual,
sensory or aphasic, when they gradually developed
over 5 minutes and when their duration was between
5 and 60 minutes. Aura was considered as atypical
when these characteristics were not present and corres-
ponded to hemiplegic, basilar or ophthalmoplegic
migraine; acute-onset aura (onset of symptoms in less
than 5 minutes) or long-lasting aura (aura lasting more
than an hour for only one symptom or more than four
hours in presence of multiple symptoms). When the
nature of a transient neurologic event was unclear,
the episode was classified as indistinguishable between
aura symptoms and a TIA.
All participants underwent a complete neurological
examination including a global evaluation of the cog-
nitive status with the Mini-Mental State Examination
(MMSE) and the Mattis Dementia Rating scale
(MDRS) and of the severity of disability with the mod-
ified Rankin scale (mRS).
Imaging data
Magnetic resonance imaging (MRI) was performed
with a 1.5 Tesla system in both centers. The sequences
and methods used for evaluating white matter hyperin-
tensities (WMH), lacunes and microbleeds have been
detailed elsewhere (11). The total volume of WMH
was normalized to the intracranial cavity (ICC) in
each patient (nWMH¼ [volume of WMH/volume
ICC]*100). The total volume of lacunes in each patient
was also normalized to the ICC (nLV¼ [volume of
lacunes/volume ICC]*100). Microbleeds were defined
as rounded foci 5mm in diameter hypointense on
gradient-echo sequences. For obtaining brain volumes
at baseline, the SIENAX algorithm was applied using
T1-weighted images as previously reported (12).
Normalized brain volumes corrected for different
skull sizes (or brain parenchymal fraction
(BPF)¼ brain volume/intracranial cavity volume)
were then used for statistical analyses. The volume of
WMH, the volume of lacunes and BPF are expressed as
percentages of the ICC volume.
Statistical analysis
A descriptive analysis was performed for the main par-
ameters obtained in the cohort. For each variable,
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percentages were calculated after excluding missing
data. Imaging and clinical parameters were compared
between patients with MA and the other patients using
both univariate analysis without adjustment and multi-
variate analysis adjusting for age, gender and current
cardiovascular risk factors (arterial hypertension, dia-
betes and hypercholesterolemia, tobacco use and alco-
hol use). The relationships between continuous and
categorical variables were tested using the Student’s
t test for univariate analysis and analysis of covariance
for multivariate analysis. The relationships between
qualitative variables were tested using the Chi2 test
and Fisher’s exact test when needed. The Cochran-
Mantel-Haenszel test was used for comparisons
between qualitative variables after adjustment for age,
gender, current cardiovascular risk factors and educa-
tional level. The threshold for statistical significance
was p< 0.05.
Results
A total of 378 CADASIL patients were included in the
study: 249 in Paris and 129 in Munich. There were 167
men (44.2%) and 211 women (55.8%); their mean age
was 51.3 years (range 23–79 years). Diagnosis was
established by genetic testing for 358 patients and by
skin biopsy for 20 patients.
Main characteristics of the entire study population
Among the 378 individuals, 206 (54.5%) had a positive
history of migraine attacks. There were 234 (61.9%)
who had had at least one cerebrovascular event (366
ischemic strokes, three hemorrhagic strokes and 108
transient neurologic episodes considered as TIA or as
indistinguishable between TIA and aura). Previous or
persisting psychiatric or mood disturbances were
observed in 164 patients (43.4%). A total of 181
patients (47.9%) complained of memory or concentra-
tion difficulties and 43 suffered from dementia (11.4%).
Thirty-five patients (9.3%) presented at least one epi-
leptic seizure.
On MRI, all patients but one had WMH. The MRI
results are detailed in the supplementary material. Only
a single patient had a normal MRI. This patient was a
32-year-old man who reported a single episode of
visual-sensory-aphasic aura without headache and
had a normal clinical examination. He carried a typical
mutation in the NOTCH3 gene.
Global features of headache episodes in the study
population
A total of 206 were found to have a positive history of
migraine attacks in the cohort (54.5% of the cohort).
The frequency of the various subtypes of migraine
attacks in the cohort population is detailed in Table 1.
There were 173 individuals, representing 45.8% of
the whole cohort or 84% of the migraine patients,
who had a history of MA attacks. Among them,
54 patients also reported MO attacks.
Thirty-three patients (8.7% of the whole cohort)
reported MO attacks only.
In both groups, there was a majority of women:
62.4% of individuals with MA, and 60.6% of those
with MO attacks only were women.
Main characteristics of MO attacks in the
study population
Among the 87 patients with MO attacks (33 with MO
attacks only and 54 patients with both MO and MA
attacks), the first episode of MO occurred between
16 and 30 years of age in 42 individuals (48%). The fre-
quency of MO attacks over the past two years and
according to age is shown in Figure 1. This frequency
was largely variable frommore than one attack per week
to less than one every two years, but in most cases the
frequency was low (less than one attack per month in
64.4% of MO patients). Other characteristics of MO
attacks are detailed in the supplementary material.
Main characteristics of MA attacks in the
study population
Among the 173 individuals with MA attacks, the peak
age at onset of MA attacks was between 16 and
30 years in women and between 31 and 40 years in
men (Figure 2). Among individuals with MA attacks,
54.2% of women had their first MA attack before they
were 30 years old while 26.15% of men had their first
attack before the same age limit (p¼ 0.0003).









# MA attacks (total) 173 (45.8%) 108 (62.4%)
- MA attacks only 119 (31.5%) 71 (59.7%)
- MA attacksþMO attacks 54 (14.3%) 37 (68.5%)
# MO attacks (total) 87 (23%) 57 (65.5%)
- MO attacks only 33 (8.7%) 20 (60.6%)
Others types
- Episodic tension type 85 (22.5%) 46 (54.1%)
- Chronic tension type 19 (5%) 9 (47.4%)
MA: migraine with aura; MO: migraine without aura.
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The frequency of MA attacks during the two years
before inclusion was found to vary widely among
patients but was relatively low since 80.2% of patients
reported less than one attack per month (Figure 1).
Among the 139 patients with MA who reported
headache associated with aura, 87 (65%) reported
hemicranial pain during their MA attack, 89 (66.4%)
pulsatility, 99 (74.5%) phonophobia and 98 (73.7%)
photophobia. In addition, 83 (62.5%) complained of
nausea and 57 (43.2%) had vomiting during their head-
ache. The mean duration of headache was between

































































Figure 1. Frequency of MO and MA attacks over the past two years in CADASIL patients according to age.
MO: migraine without aura, MA: migraine with aura; CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; yo: years old.



























Figure 2. Age at onset of MA according to gender.
The peak age at onset of MA attacks is between 16 and 30 years in women and between 31 and 40 years in men.
MA: migraine with aura; yo: years old. Missing data for one female individual.
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than 4 hours in 37 (30.6%). Only two participants with
MA (1.7%) reported headache episodes of more than
72 hours. For 11 patients (9.1%), the mean duration of
headache could not be assessed.
Common triggers of MA attacks such as stress, anx-
iety or fatigue were detected in 42 patients (24.4%).
Eight women reported menstrual MA attacks (corres-
ponding to 7.4% of women with MA); only one had
pure menstrual MA.
Aura symptoms during MA attacks in the
study population
Visual symptoms during MA were reported by 141
patients (82% of patients with MA attacks), sensory
symptoms occurred in 126 patients (73.3%), aphasia
in 96 (55.8%) and motor symptoms in 35 (20.3%).
Scintillating scotoma was the most frequent visual
symptom reported by 80 (46.5%) patients with MA.
Lateral homonymous hemianopia, phosphenes and
blindness (visual field alteration preventing them from
discerning the main characteristics of the environment)
were reported respectively by 44 (25.6%), 37 (21.5%)
and three (1.7%) MA patients. Sensory symptoms
involved the arm in 119 patients with MA (69.2%),
the face in 83 (48.3%) and the leg in 47 (27.3%).
Speech disturbances during aphasic auras included
alterations of oral expression in 66 patients (38.4%),
paraphasia in 30 (17.4%), dysarthria in 18 (10.5%)
and impaired comprehension in seven (4.1%). Motor
symptoms were reported in the arm in 32 patients with
MA (18.6%), in the leg in 15 (8.7%) or face in 10
(5.8%). Thirty-seven patients (21.5% of patients with
MA) reported only one type of aura symptom. Twenty-
two patients (12.8% of MA patients) reported only
visual aura, 12 patients (7%) only sensitive aura, one
patient (0.6%) only aphasic aura and one patient
(0.6%) only confusion (c.f. below for description of
patients with atypical auras).
A total of 119 patients (69.2% of patients with MA)
were able to report a typical ‘marche migraineuse’ with
a progression of symptoms over 5 minutes during
their auras.
For 34 patients (19.7% of patients with MA), the
aura was never accompanied by headache.
Among the 173 patients with MA, 102 (59.3%) indi-
viduals reported at least one atypical aura: 35 patients
(20.3% of MA patients) ever had motor symptoms
during their aura; 35 others previously reported basilar
or other unusual symptoms such as confusion, alter-
ations of consciousness or hallucinations (20.3%).
Fifty-three patients reported acute-onset auras
(30.8%) and eight patients long-lasting auras (4.7%).
In the present cohort, none had a history of coma or
meningism.
MA as inaugural or isolated symptom of
the disease
MA was the inaugural manifestation of the disease in
147 patients, which represents 41.1% of symptomatic
patients of our cohort. After exclusion of the 43 demen-
tia patients in order to prevent a potential recall bias,
MA remained the most frequent inaugural symptom of
the disease (in 44.4% of the 315 symptomatic patients
without dementia). Inaugural clinical manifestations of
the disease distinct from MA are reported in the sup-
plemental material.
MA was observed as the sole symptom of the disease
(no history of stroke, epilepsy, dementia or psychiatric
disorder except for a possible episode of depression) in
46 patients of the cohort (12.1%). Their mean age was
43 years (range: 25–72 years). In this subgroup of MA
patients, 26 individuals (56.5%) reported at least one
episode of atypical aura (detailed in the supplemental
material). All patients who presented MA as the sole
symptom of CADASIL at the time of the study except
one had WMH on MRI.
Inter- and intra-familial variability of the
migraine phenotype
Data obtained from seven large multiplex families with
four or more affected individuals included in the study
are reported in Figure 3. Each family comprised at least
two individuals with MA; the results showed that the
age at onset of MA can largely differ among migrain-
eurs within a same family, with a maximal difference of
about 45 years (family 3). In addition, characteristics of
aura symptoms and frequency of MA attacks also
broadly vary among related migraineurs.
The number of mutations in the cohort was too high
(71 different mutations were identified) for analyzing
potential genotype-phenotype correlations in the pre-
sent cohort.
Demographic, clinical and imaging correlates of
MA in the study population
Patients who had a history of MA were significantly
younger and comprised a larger proportion of women
than patients without MA. After adjustment for age,
gender, current cardiovascular risk factors and educa-
tional level, a positive history of MO was found signifi-
cantly more frequently in patients with MA than in the
rest of the sample. Slightly higher MMSE, MDRS
and Initiation/Perseveration MDRS subscale scores
and lower Rankin score were observed in the MA
group despite adjustment for multiple confounders
(Table 2). Similarly, better cognitive and functional per-
formances were also found in all migraine patients
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(MA and/or MO patients) in comparison with those
without migraine (Table S1, supplemental material).
Regarding the MRI parameters, there was a trend
for a lower mean number of microbleeds and a lower
load of WMH in the MA group after adjustment for
age, gender and cardiovascular risk factors (Table 2).
The lower number of microbleeds was found to be sig-
nificant when all migraine patients, including MA and/
or MO patients, were compared to the other individuals
of the cohort (Table 1S, supplementary material).
Discussion
In this large cohort of CADASIL patients, the preva-
lence of migraine attacks exceeded 50% of individuals
and appeared higher than previously reported in the
literature (4–6,13). The use of a structured interview
for diagnosis and prospective recruitment of patients,
obtained only in the present study, may explain this
discrepancy. In addition, selection bias related to the
centralization of recruitment in each country cannot
be totally excluded. This high prevalence appears
mainly related to the 45.8% prevalence of MA in the
sample, which is nearly 10 times higher than that
observed in the general population. The small differ-
ence in the prevalence of MA between men and
women in CADASIL patients contrasting with the 1:2
male:female ratio in the general population further
illustrates the specific consequences of the genetic dis-
ease. In contrast, MO attacks are reported only by 23%
of individuals in the cohort. This frequency is two times
lower than the frequency of MA in the sample and
appears only slightly higher than the prevalence of
MO in the general population, varying from 6% to
18% (7,8,14,15). MO attacks were also detected in
18% of men and 28% of women, which is close to
the sex ratio of MO in the general population (8).
Finally, MO attacks were reported two times more fre-
quently in CADASIL patients with MA than in those
without MA which suggests that the predisposition for
MA in CADASIL may favor, but only moderately, the
co-occurrence of MO attacks.
There is accumulating evidence supporting a causal
relationship between cortical spreading depression
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Figure 3. Migraine phenotype in seven French CADASIL families with more than four CADASIL patients in the cohort.
(A) A vertical rod represents a patient and the height of the rod indicate his or her age at inclusion.
Patients within a single family are grouped and families are numbered from f1 to f7. The orange bands represent age at MA onset and
the blue-hatched areas indicate age at MO onset.
(B) The red crosses indicate the mean frequency of MA attacks and the blue crosses indicate the mean frequency of MO attacks during
the two years before inclusion.
(C) This panel gives information about the MA symptoms. The yellow strips indicate patients having only typical auras whereas the
green strips indicate patients reporting atypical auras. Symptoms are represented by a capital letter (V: Visual, S: sensory, A: aphasic, M:
motor, C: confusion and/or decreased level of consciousness). Patients reporting acute-onset auras are specified with a red lightning
symbol.
CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; MA: migraine with aura;
MO: migraine without aura.
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(CSD) and aura symptoms. Different factors were
found capable of modulating the threshold for trigger-
ing CSD in experimental data (16–19). In trans-
genic mice over-expressing NOTCH3 mutations,
Eikermann-Haerter et al. detected an enhanced
susceptibility to CSD (20). The exact origin of this
reduced threshold for CSD remains unknown. In
the CADASIL mouse model, this is observed in the
absence of major reduction of cortical blood flow.
In humans, our results confirm that MA is mostly
reported at the earliest stage of the disease and was
even the inaugural manifestation in 41% of individuals.
Thus, aura symptoms usually occur when ischemic
manifestations of the disease have not yet begun.
Aura symptoms can also occur in the absence of MRI
lesions in CADASIL (21) as observed in a single indi-
vidual of our cohort. In addition, our results also sug-
gest that the frequency of MA attacks decreases at the
advanced stage of the disease when both ischemic
lesions and manifestations are increasing. Other studies
are needed to determine whether changes occurring at
the cortex level in myelin content or in microglial or
neuronal activity during the progression of the disease
are involved (22,23). Altogether, these data further sup-
port that cerebral ischemia is not the primary mechan-
ism of aura symptoms in CADASIL and that
mutations of the NOTCH3 gene are actually respon-
sible for early changes in cortical excitability in
humans. Otherwise, the prevalence of tension type-
headache (TTH) appears to be quite low in our
cohort in comparison to its prevalence in the general
population. However, we cannot exclude that TTH has
been masked by the frequent occurrence of migraine
headache in our patients, or by the use of antalgic treat-
ments, thus leading to an underestimation of prevalence
of TTH in our CADASIL cohort.
In the present study, we found a significant female
preponderance among CADASIL patients with MA.
Age of onset of MA was also significantly lower in
women than in men. These results are in line with
Table 2. Differences observed between patients with MA and patients without MA.
Migraine with aura
Yes (n¼ 173) No (n¼ 205) pa pb
Mean age (range) 47.8 (25–72) 54.2 (23–79) <0.0001
Women 62.4% 50.2% 0.018 <0.0001
Cardiovascular risks factors
Alcohol consumption >2 drinks per dayc 5.3% 9.9% 0.095
Current or past smokers 52.6% 54.6% 0.693
Arterial hypertension 17.3% 25.5% 0.056
Diabetes 1.2% 3.9% 0.117
Hypercholesterolemia 33.1% 47.8% 0.004
Associated neurological signs
MO 31.2% 16.1% 0.0005 0.01
Stroke 53.8% 68.8% 0.0027 0.23
Psychiatric disorder 40.5% 45.9% 0.29 0.38
Epilepsy 6.4% 11.7% 0.077 0.30
Dementia 6.9% 15.2% 0.012 0.25
Mean MMSE (SD) 27.97 (3.0) 25.59 (5.3) <0.0001 0.0015
Mean Rankin (SD) 0.66 (1.1) 1.40 (1.5) <0.0001 0.002
Mean MDRS (SD) 137.7 (12.3) 129.6 (21.3) <0.0001 0.0143
Mean I/P MDRS subscale (SD) 34.9 (4.6) 31.3 (8.3) <0.0001 0.007
MRI parameters
WMH volume, mean (SD) 0.0681 (0.05) 0.0734 (0.05) 0.318 0.07
Lacunar volume, mean (SD) 2.59.104 (5.3.104) 2.61.104 (4.5.104) 0.96 0.28
Microbleeds, mean (SD) 1.29 (4.3) 5.91 (17.3) <0.0001 0.05
BPF, mean (SD) 86.46 (5.3) 84.24 (7.2) 0.003 0.48
(a) p value without adjustment. (b) p value obtained after adjustment for age, gender, cardiovascular risk factors, educational level. (c) >2 drinks per day
for men and >1 drink per day for women.
BPF: brain parenchymal fraction; MDRS: Mattis Dementia Rating Scale; I/P MDRS: Initiation/Perseveration MDRS; MMSE: Mini-Mental State
Examination; SD: standard deviation; WMH: white matter hyperintensities; MO: migraine without aura.
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previous findings in CADASIL (9,24). They are also in
agreement with the female preponderance of migrain-
eurs in the general population, although more pro-
nounced for MO than for MA (7,14,25,26). Our data
suggest that, in addition to the genetic defect, the hor-
monal status may continue to influence the occurrence
of MA in CADASIL patients. Female hormones have
been repeatedly shown to facilitate CSD in different
animal models (18,19,27). In transgenic mice with
NOTCH3 mutations, females were also found to have
a lower CSD trigger threshold than males although the
difference did not reach statistical significance (20).
Some authors previously raised the hypothesis that
MO could also result from silent waves of CSD
(28,29). The disproportionate increase of MA attacks
compared to MO attacks in CADASIL do not favor
this interpretation. We also observed that the age at
onset, characteristics of aura symptoms and frequency
of attacks vary broadly among migraineurs within the
same family, which suggests that the genetic familial
background may not have a significant influence on
the development of MA symptoms in CADASIL.
Almost 60% of individuals with MA in the cohort
already experienced at least one atypical aura consist-
ing of unusual symptoms such as motor deficit, loss of
consciousness, fever, acute onset or long-lasting aura.
The high incidence of atypical MA attacks has already
been reported (9) and may raise important diagnostic
difficulties. Particularly, acute-onset aura was detected
in one-third of MA patients in this cohort and may be
difficult to discriminate from TIAs. The frequent occur-
rence of ‘‘positive’’ neurologic symptoms such as par-
esthesia or visual scintillations or the stereotyped
nature of repetitive attacks are then particularly helpful
for their recognition. Moreover, when the nature of a
symptom was uncertain, the episode was classified as an
episode indistinguishable between aura and TIA in the
present study, thus reducing the risk of overestimation
of aura symptoms. In the absence of other manifest-
ations of the disease, the occurrence of atypical aura
may also be useful for suggesting the diagnosis of
CADASIL, particularly in at-risk individuals or in the
presence of MRI signal abnormalities. In our patients
with MA who had a normal neurological examination
and no other symptom of the disease except possible
depression, atypical aura was detected in more than
half of individuals.
In our cohort, we observed that patients with MA
had globally a better functional and cognitive outcome
than the other individuals. After adjustment for mul-
tiple confounding factors, patients with MA had higher
MMSE and MDRS scores and lower Rankin scores
than the other participants. These results further sup-
port that the occurrence of MA is not associated with
the development of ischemic lesions and disability in
CADASIL and may even present some protective
effects. There are experimental data showing that
CSD may induce long-lasting brain protection against
the development of ischemic lesions (30,31). We think
however that these findings should be interpreted with
caution. Particularly, some recall biases cannot be
totally excluded. For instance, patients with alterations
in their memory performances are less likely to report
their past history of migraine attack in comparison to
patients with preserved cognitive functions. In addition,
the frequent use of aspirin in patients who had a stroke
may influence the occurrence of MA attacks and con-
sequently their recognition. More, we note a trend
toward a lower proportion of stroke in the group of
patients with MA, but this result should be interpreted
with caution because episodes ‘‘indistinguishable
between aura and TIA’’ have been classified as stroke,
and this could have introduce a bias due to a misclassi-
fication of such episodes.
Clinical implications
. Migraine with aura, observed in almost half of all cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy (CADASIL) patients, is the most frequent inaugural symptom of the
disease and can remain isolated.
. The occurrence of atypical aura should evoke the diagnosis of CADASIL, particularly in the presence of
white-matter lesions or in a suggestive familial context, since almost 60% of migraine CADASIL patients
report atypical aura.
. Migraine with aura does not appear to be associated with a negative prognosis in CADASIL.
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de Recherche Clinique of Saint-Louis/Lariboisiere Hospital,
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